Quick Facts: Uses of Fosfomycin

• Target Condition: Uncomplicated urinary tract infections (UTIs).
• Specific Use: Management of acute cystitis in women.
• Target Microorganisms: Due to susceptible strains of Escherichia coli and Enterococcus faecalis.

---

Fosfomycin is a prescription medication studied for its potential to help manage specific types of bacterial infections. The oral formulation is indicated for the treatment of uncomplicated urinary tract infections (UTIs) in women. This includes acute cystitis caused by susceptible isolates of certain bacteria, primarily Escherichia coli and Enterococcus faecalis.

Using this medication may support the resolution of symptoms associated with these infections. It is a one-time oral dose regimen that is generally considered a therapeutic option for patients with uncomplicated UTIs. The goal of treatment is to address the underlying bacterial cause of the condition.

For more detailed information regarding the approved use and safety of this medication, patients and caregivers should consult the prescribing information.

The eligibility for Fosfomycin use is defined by strict regulatory criteria, specifying populations who may use the medicine and those who must not.

Eligibility Scope

Category	Official Regulatory Status / Rule
Populations for whom use is allowed	Females and female adolescents (typically 12 years of age and older) for the approved indication.
Populations for whom use is contraindicated	Patients with known hypersensitivity to fosfomycin or any excipient. Patients with severe renal failure (Creatinine Clearance < 10 mL/min or < 30 mL/min depending on the region/formulation). Patients undergoing haemodialysis.
Populations for whom use is not recommended	Pediatric patients (children below 12 years) for the oral formulation. Pregnant and breastfeeding patients, unless clearly necessary.

Condition-Specific Eligibility

Age and physiological state impose specific limits. The oral formulation’s safety and efficacy are not established in children under 12, making its use not recommended in that age group. Use is contraindicated in patients with severe renal impairment due to reduced drug excretion. Additionally, use is restricted in patients with certain hereditary metabolic disorders (e.g., fructose intolerance) due to excipients in the granule formulation.

Pregnancy and Lactation

Fosfomycin use is generally not recommended during pregnancy and lactation. Regulators advise use only if the benefit is determined to clearly outweigh the potential risk, as the drug is known to be excreted in human milk.

Interactions with other medicines and products

Fosfomycin's interaction profile is officially documented around pharmacokinetic and pharmacodynamic effects, as specified in regulatory prescribing information. The following substances and medicinal product classes are formally cited in official labeling:

Contraindicated Combinations

Co-administration with live bacterial vaccines is contraindicated. This includes agents such as BCG Vaccine Live and Cholera Vaccine (Live), due to the risk of the antibiotic causing pharmacodynamic antagonism and diminishing the vaccine's therapeutic effect.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance	Official Interaction Outcome
Metoclopramide	Reduces the absorption, leading to lower serum concentrations and decreased urinary excretion. Regulators advise this combination should be avoided.
Oral Anticoagulants	Increased risk of bleeding due to officially reported cases of elevated anticoagulant activity when co-administered. Monitoring may be necessary.
Food (Oral form)	Reduces the maximum serum concentration (Cmax) of the oral formulation, but the total amount excreted in the urine over time remains unchanged.
Cimetidine	Officially documented as having no significant effect on the pharmacokinetics of the oral formulation.

Other Regulatory Constraints

The presence of renal impairment significantly decreases Fosfomycin's excretion, which results in a prolonged elimination half-life and extended exposure. While food reduces peak concentrations, the duration of adequate urinary concentration is sustained, allowing some regulatory bodies to state the oral product can be taken without regard to food.

How Fosfomycin Works

Fosfomycin's mechanism of action begins with its entry into the bacterial cell via active transport mimicry, where it hijacks the GlpT and UhpT nutrient transporters to reach the cytoplasm. Once intracellular, the drug functions as a suicide inhibitor by targeting the essential enzyme UDP-N-acetylglucosamine enolpyruvyl transferase ( MurA) .

Fosfomycin forms a permanent covalent bond with a cysteine residue in the MurA active site, irreversibly halting the first committed step in peptidoglycan synthesis. This blockade prevents the formation of the cell wall's crucial building blocks. The absence of a completed, rigid cell wall makes the bacterium incapable of maintaining osmotic homeostasis. This structural collapse causes the bacterial cell to rupture due to internal pressure, resulting in a bactericidal physiological effect. This mechanism is highly dependent on the function of the GlpT and UhpT transporters; their down-regulation by the bacteria is a primary mechanistic limitation.

How to Use Fosfomycin

Fosfomycin is administered via two distinct routes, depending on its specific formulation and intended use. The medicine is supplied as the tromethamine salt for oral use and as the disodium salt for intravenous (IV) administration. The administration protocol follows established guidelines for each form.

---

Official Administration Protocols

Administration Route	Standard Adult Dosing	Frequency and Schedule
Oral (Granules)	Single 3 g dose of fosfomycin	Single, non-repeated course for uncomplicated use
Intravenous (IV)	3 g to 8 g total per day	Divided doses, typically every 6 or 8 hours for systemic infections

---

Preparation and Timing

For the oral formulation, the full contents of the sachet must be completely dissolved in approximately 120 mL (four ounces) of cold water and ingested immediately. To achieve optimal absorption, this single dose is taken without food, ideally two to three hours before or after a meal.

For IV administration, the powder requires reconstitution and further dilution with an appropriate intravenous fluid by a healthcare professional. The prepared solution is then administered as a slow intravenous infusion over a period ranging from 15 to 60 minutes.

Dosing Adjustments

For the IV formulation, dose adjustment and/or prolongation of the dosing interval is mandatory for patients presenting with significantly reduced kidney function (renal impairment). Pediatric dosing for the IV form is calculated based on body weight.

Evidence for Uncomplicated Urinary Tract Infections (uUTIs)

Research on the use of Fosfomycin for simple bladder infections, or acute cystitis, primarily involves short-term Randomized Controlled Trials (RCTs). These studies were designed to compare single-dose oral Fosfomycin against other common antibiotics used for the same condition. The research examined two key measurements: clinical success (whether symptoms like painful urination were observed to change) and microbiological eradication (how studies measured the status of bacteria causing the infection). For this specific, uncomplicated use, the overall body of evidence is broadly described as having a moderate level of certainty. Research has also explored the use of Fosfomycin in pregnant individuals with asymptomatic bacteriuria.

---

Evidence for Serious Infections and Complicated UTIs (Intravenous)

Research exploring the use of Fosfomycin for more serious, systemic infections—including complicated urinary tract infections (cUTIs) and pyelonephritis—involved a wider variety of study designs. This research examined both RCTs and observational studies from clinical settings. These studies monitored outcomes related to functional imbalance and physiological strain, such as overall success (defined as a specific status of clinical symptoms and bacterial status) and, in the most severe cases, mortality (survival). Fosfomycin was frequently co-administered with other antibiotics as part of a combination therapy regimen in the research studies. The overall evidence base for these specific, severe uses is often labeled as Moderate/Low.

---

What Remains Uncertain in the Research

A primary gap is the limited information for long-term outcomes across all indications; most studies only observed responses over defined short or intermediate time intervals. For the complicated and systemic infections, the evidence quality varies across studies, and there is a documented need for more large-scale, dedicated RCTs to clarify outcomes. Furthermore, the use of combination therapy in most severe cases means the research provides limited insight into Fosfomycin's independent contribution when used alone. The research also highlights that subgroup findings are uncertain or insufficient for patient groups such as children (pediatric patients).

Fosfomycin storage and disposal are strictly governed by regulatory requirements to maintain product stability and ensure environmental safety.

Official Storage Conditions

Formulation	Temperature Requirement	Handling/Stability Constraint
Oral Granules	Store at 25 C (77 F), with permitted excursions to 30 C (86 F).	Protect from moisture and direct sunlight. Use solution soon after dissolving granules.
IV Powder	Store below 25 C.	Must be protected from freezing. Solution for infusion is for single use only.

All Fosfomycin formulations must be kept out of the reach of children.

Disposal Instructions

Unused or expired Fosfomycin product and associated waste material must be disposed of in accordance with local requirements. The medicine should not be discarded via wastewater or household garbage unless specifically instructed to do so by the local regulator.